Dogs get cancer, just like humans. Scientists at the University of Veterinary Medicine, Vienna are now exploring the molecular basis of cancer progression in canine cell lines. Modern cancer therapy has been revolutionized with the introduction of new drugs, so-called ‘targeted drugs’, but the basis for the application of these new agents in cancer therapy is a deep understanding of the molecular mechanisms of the disease, even with pets. Now a research team led by Sabine Macho-Maschler has investigated the activation of genetic regulatory mechanisms in canine cells and found both matches as well as differences compared to man.
Almost every second dog above the age of ten years develops cancer. Modern tumor therapy combines surgery, radiation therapy and novel drug treatment options. While surgery and radiotherapy ensure adequate treatment for all animals at the University of Veterinary Medicine, Vienna, there is a growing gap in the treatment with modern therapeutics.
The reason for this is that modern targeted agents are based on specific molecular genetics findings, which are not easy to transfer to dogs from humans or the preferred animal model in cancer research, the mouse. So to make modern cancer drugs also accessible to our four-legged friends requires comparative research into the molecular basis of cancer in dogs.
Molecular causes constitute an important basis for modern treatment concepts
Our understanding of the molecular and cellular causes that are responsible for the development of cancer has grown strongly in recent years. This knowledge aids us in combating cancer cells with a growing number of new drugs.
However, since cancer may manifest itself differently in each patient, an extensive molecular study of the existing mutations in cancer cells is an important prerequisite for successful therapy. This is because the targeted agents can only actually help when the cancer cells possess the corresponding molecular structures against which the drug is designed to act. The success of treatment with targeted drugs requires a molecular diagnosis, as basis for the so-called ‘personalized medicine’ in cancer research.
Investigation into the molecular mechanisms of metastasis in canine cells
A research team at the Unit of Molecular Genetics have investigated an important process in the molecular genetics of cancer development in canine cell lines. These cell lines have long been used by researchers to analyze pathological processes and now were analyzed for changes in the expression of several RNA-species using next generation sequencing.
"Cancer researchers have been working for many years on the transition of epithelial tumor cells into the more aggressive mesenchymal state. Important gene switches could be identified in this process with potential for use as therapeutic targets: these gene products could be targeted with novel therapeutics”, explained Macho-Maschler, who headed the now published study. Research on epithelial-mesenchymal transition (EMT) has so far mainly focused on cells of mice and humans and showed how certain signaling pathways cooperate to allow cancer cells metastasis. Metastases are formed when the originally sedentary cancer cells obtain certain properties, which allow them to migrate into another organ and to form a new tumor there.
“In the majority of cases it is the metastases that cost the patient’s live, as the original tumor can often be well controlled by radiation and surgery," emphasized Mathias Müller, head of the Institute for Animal Breeding and Genetics. "We are interested in what is going on at the molecular level during metastasis, as it is likely that we can use this knowledge for the successful treatment of metastases."
The basis for further research has been laid
The molecular analysis of EMT is considered by researchers as a model for the acquisition of the ability to metastasize. The TGF-beta pathway has for a long time been recognized as a central switch in this process. Macho-Maschler expressed her satisfaction with the many similarities seen in the comparative analysis of results for canine, human and mouse cells. "TGF-beta, for example, also plays an important role in dogs, but there are also interesting variations," reports Macho-Maschler. Her recent BMC Genomics publication is filled with long lists of RNAs that are regulated during EMT.
These findings should serve as a basis for further analysis. Macho-Maschler is skeptical as to whether their research can improve the treatment of dogs with cancer in the near future. "Our newly published results are like a catalogue, perhaps an important requirement for new approaches and ideas. Ultimately, we do not even know whether many of the new drugs actually act in canine cells. There are, for example, targeted drugs which act only in humans but not in mice" says Macho-Maschler to dampen unrealistic expectations.
In humans, a much more comprehensive catalogue was completed this year; "The Cancer Genome Atlas" makes available to researchers the essential information contained within 11,000 genetically analyzed patient samples (cancergenome.nih.gov). It is an important resource, which enables researchers quickly and reliably to check the frequency of certain genetic changes in a cancer. The catalogue published by Macho-Maschler is naturally not comparable with the TCGA, but it is a first important step in the same direction for canine cancer.
The article “High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells”, by Priyank Shukla, Claus Vogl, Barbara Wallner, Doris Rigler, Mathias Müller and Sabine Macho-Maschler was published in BMC Genomics. doi:10.1186/s12864-015-2036-9 http://www.biomedcentral.com/1471-2164/16/944
About the University of Veterinary Medicine Vienna
The University of Veterinary Medicine Vienna (Vetmeduni Vienna) is one of the leading veterinary, academic and research facilities in Europe. Its main focus is on the research fields of animal health, food safety, animal husbandry and animal welfare as well as biomedical fundamentals. The Vetmeduni Vienna has 1,300 employees and is currently training 2,300 students. The campus in Floridsdorf, Vienna has five university hospitals and numerous research institutions at its disposal. Two research institutes at Wilhelminenberg, Vienna and a Teaching and Research in Lower Austria also belong to the Vetmeduni Vienna. In 2015, the Vetmeduni Vienna is celebrating the 250th anniversary of its founding. http://www.vetmeduni.ac.at
Dr. Sabine Macho-Maschler
University of Veterinary Medicine Vienna
Institute for Animal Breeding and Genetics
T +43 1 25077- 5627
Science Communication / Corporate Communications
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-1153
Dr. Susanna Berger | Veterinärmedizinische Universität Wien
Bolstering fat cells offers potential new leukemia treatment
17.10.2017 | McMaster University
Ocean atmosphere rife with microbes
17.10.2017 | King Abdullah University of Science & Technology (KAUST)
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
17.10.2017 | Life Sciences
17.10.2017 | Life Sciences
17.10.2017 | Earth Sciences